Sialylation enhances the secretion of neurotoxic amyloid-beta peptides |
| |
Authors: | Nakagawa Kazuhiro Kitazume Shinobu Oka Ritsuko Maruyama Kei Saido Takaomi C Sato Yuji Endo Tamao Hashimoto Yasuhiro |
| |
Affiliation: | Glycochain Functions Laboratory, Suprabiomolecular System Group, Frontier Research System, RIKEN, Wako-shi, Saitama, Japan. |
| |
Abstract: | Alzheimer's disease (AD) is characterized by amyloid-beta peptide (Abeta) deposition in the brain. Abeta is produced by sequential cleavage of amyloid precursor protein (APP) by beta-secretase (BACE1: beta-site APP-cleaving enzyme 1) and gamma-secretase. Previously, we demonstrated that BACE1 also cleaves beta-galactoside alpha2,6-sialyltransferase (ST6Gal-I) and down-regulates its transferase activity. Here, we report that overexpression of ST6Gal-I in Neuro2a cells enhanced alpha2,6-sialylation of endogenous APP and increased the extracellular levels of its metabolites [Abeta by two-fold, soluble APPbeta (sAPPbeta) by three-fold and sAPPalpha by 2.5-fold). Sialylation-deficient mutant (Lec-2) cells secreted half as much Abeta as wild-type Chinese hamster ovary (CHO) cells. Furthermore, wild-type CHO cells showed enhanced secretion of the APP metabolites upon ST6Gal-I overexpression, whereas Lec-2 cells did not, indicating that the secretion enhancement requires sialylation of cellular protein(s). Secretion of metabolites from a mutant APP (APP-Asn467,496Ala) that lacked N-glycosylation sites was not enhanced upon ST6Gal-I overexpression, suggesting that the N-glycans on APP itself are required for the enhanced secretion. In the mouse brain, the amount of alpha2,6-sialylated APP appeared to be correlated with the sAPPbeta level. These results suggest that sialylation of APP promotes its metabolic turnover and could affect the pathology of AD. |
| |
Keywords: | amyloid-beta amyloid precursor protein sialylation β-galactoside α2, 6-sialyltransferase |
本文献已被 PubMed 等数据库收录! |
|